• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CPRIT gives $81 million to cancer research

CPRIT gives $81 million to cancer research

March 30, 2012
CenterWatch Staff

The Cancer Prevention and Research Institute of Texas (CPRIT) has given an excess in funding of $81 million to support cancer research and commercialization projects in Texas.

Funding includes $20 million for a Houston-area pre-commercialization center to “incubate” promising oncology-focused technologies, as well as three CPRIT Scholar in Cancer Research awards to attract top investigators in oncology research to Texas. Others include:

  • Dallas-Fort Worth and San Antonio initiatives aiming to improve safety and quality of life for cancer patients by testing targeted therapy approaches to treatment.
  • A Houston-based project examining methods to improve patient response to pain relief drugs, and another project to significantly reduce time for analyzing patient genomes by isolating gene sequencing to only the fraction of genes that, when mutated, contribute to the majority of cancer cases.
  • A College Station facility designed to enhance the state’s manufacturing capabilities for emerging cancer drug discoveries that are ready for clinical studies or commercial launch.
  • A Dallas program investigating the efficacy of a therapeutic agent that some cancer cells metabolize to produce hydrogen peroxide to “disinfect” and kill themselves.

In addition, Cell Medica, a cellular immunotherapies developer for oncologic applications, will relocate its headquarters from the U.K. to Texas, bringing with it jobs and plans to establish a manufacturing and distribution facility in the state.

“CPRIT is proud to fund groundbreaking research that will advance therapeutic and supportive care approaches to cancer treatment,” said Jimmy Mansour, founding chairman of CPRIT’s governing board. “We’re confident that our efforts to bring the best facilities and brightest minds in oncology to Texas will continue to reduce both the human and economic costs of this disease in our state and beyond.”

The 25 newly funded projects bring the total amount of grants by CPRIT since its inception in 2007 to more than $650 million.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing